Enliven Therapeutics, Inc. (ELVN)
NASDAQ: ELVN · Real-Time Price · USD
42.98
-1.92 (-4.28%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Enliven Therapeutics Employees
Enliven Therapeutics had 60 employees as of December 31, 2025. The number of employees decreased by 2 or -3.23% compared to the previous year.
Employees
60
Change (1Y)
-2
Growth (1Y)
-3.23%
Revenue / Employee
n/a
Profits / Employee
-$1,728,233
Market Cap
2.57B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 60 | -2 | -3.23% |
| Dec 31, 2024 | 62 | 16 | 34.78% |
| Dec 31, 2023 | 46 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Zai Lab | 1,784 |
| ADMA Biologics | 647 |
| Beam Therapeutics | 511 |
| Tarsus Pharmaceuticals | 370 |
| Vera Therapeutics | 249 |
| Celldex Therapeutics | 198 |
| Soleno Therapeutics | 182 |
| Immunome | 177 |
ELVN News
- 2 months ago - Enliven Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference - Transcripts
- 2 months ago - Enliven Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference - PRNewsWire
- 3 months ago - Enliven Therapeutics Early Leukemia Drug Results Impress, Stock Soars - Benzinga
- 3 months ago - Enliven Reports Positive Initial Phase 1b Data for ELVN-001 in CML and Outlines 2026 Clinical Milestones - PRNewsWire
- 3 months ago - Enliven Therapeutics Bolsters Board to Prepare for Next Phase of Development - PRNewsWire
- 4 months ago - Enliven Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules - PRNewsWire
- 4 months ago - Enliven Therapeutics Announces New CEO to Drive Next Phase of Development - PRNewsWire
- 5 months ago - Enliven Therapeutics Transcript: Jefferies London Healthcare Conference 2025 - Transcripts